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  EVIDENCE-BASED ANSWER 
Angiotensin-converting enzyme (ACE) inhibitors make a significant difference for patients with diabetes as a 
whole. If patients both with and without microalbuminuria are included together, ACE inhibitors significantly 
reduce the progression of the albumin excretion rate (strength of recommendation [SOR]: A, based on multiple 
randomized controlled trials) and the development of overt nephropathy (SOR: A, based on 1 randomized 
controlled trial). 
However, studying diabetes without microalbuminuria separately, the effect of ACE inhibitors on progression to 
nephropathy does not reach statistical significance. This applies to both type 1 and 2 diabetes (SOR: A, based 
on randomized controlled trials with heterogenous results). Results are contradictory regarding whether ACE 
inhibition delays new onset of diabetic microalbuminuria. 
  EVIDENCE SUMMARY 
There are 3 prospective randomized controlled trials studying the effect of ACE inhibitors on albumin excretion 
for patients with diabetes who do not have microalbuminuria. A 2-year randomized controlled trial compared 
lisinopril (Prinivil; Zestril) 10 mg/d with placebo in 530 normotensive adults (aged 20–59 years) with insulin-
dependent diabetes, defined as those diagnosed with diabetes before age 36 and using continuous insulin 
therapy within 1 year of diagnosis. At the beginning of the study, 90 patients had microalbuminuria—defined as 
an albumin excretion rate (AER) >29 mg/24 hr—and 440 patients did not. When the results for all patients who 
had and did not have microalbuminuria were combined, there was a significantly smaller rise in the AER for the 
lisinopril group vs the placebo group (3.2 mg/24 hr lower; P=.03). However, for the patients without initial 
microalbuminuria, the reduction in the rise of AER with lisinopril was not significant (1.4 mg/24 hr lower; P=.10). 
The decreased rate of developing new microalbuminuria was also not significant (relative risk reduction 
[RRR]=12.7%; P=.10).1 
A subsequent trial compared enalapril (Vasotec) 10 mg/d with placebo in 194 normotensive patients (aged 40–
60) with type 2 diabetes and without microalbuminuria, defined as AER >30 mg/24 hr. Over the 6-year course 
of the study, the AER in the placebo group rose from 10.8 mg/24 hr to 26.5 mg/24 hr. The AER of the 
treatment group dropped from 11.6 mg/24 hr initially to 9.7 mg/24 hr at 2 years, then rose to 15.8 mg/24 hr at 6 
years. Enalapril significantly slowed the rise in AER (RRR=0.4; P=.001). Nineteen percent of the placebo group 
developed microalbuminuria, compared with 6.5% of those taking enalapril (absolute risk 
reduction[ARR]=12.5%; number needed to treat=8; P=.042). While this study described a modest and 
statistically significant renal protective effect of enalapril, it did not use an intention-to-treat analysis.2 
MICRO-HOPE, a subset of the HOPE trial, studied ramipril (Altace) 10 mg/d vs placebo in 2437 patients with 
diabetes who did not have clinical proteinuria. Patients were aged 55 years or older and had either a previous 
cardiovascular event or at least 1 other cardiovascular risk factor. There were 1140 patients with 
microalbuminuria, defined as an albumin/creatinine ratio 2 mg/mmol, and 2437 patients without. After 4.5 
years, 10% of patients had developed overt nephropathy, defined as albumin/creatinine >36 mg/mmol. 
When all patients in the study were examined together, ramipril provided significant renal protection over 
placebo (RRR=24%; ARR=1%; P=.027). It also lowered the risk of MI by 22%, stroke by 33%, and 
cardiovascular death by 37%. But in a separate analysis of the patients without microalbuminuria, ramipril did 
not significantly reduce overt nephropathy (P=.50). Ramipril also did not significantly reduce the risk of 
developing new microalbuminuria in this group (RRR=9%; P=.17). Further, for patients without 
microalbuminuria, ramipril did not reduce the combined outcomes of myocardial infarction, stroke, or 
cardiovascular death (odds ratio=0.85; 95% CI, 0.70–1.02).3 
  RECOMMENDATIONS FROM OTHERS 
We could find no guidelines recommending for or against the use of ACE inhibitors for patients with diabetes 
without microalbuminuria. 
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ACE inhibitors should still be used in most patients 
with type 2 diabetes 
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ACE inhibitors do not prevent the development of type 2 diabetic nephropathy. In contrast 
to type 1 diabetes, cardiovascular disease is the primary cause of death in type 2. The 
HOPE study demonstrated that ACE inhibitor therapy significantly reduces cardiovascular 
events in type 2 diabetes independent of hypertension status.4 These benefits are so 
compelling that the American Diabetes Association strongly recommends ACE inhibitor 
therapy for type 2 diabetics aged ≥55 years with 1 additional risk factor.5 Despite not 
preventing the development of nephropathy, ACE inhibitors should be used for most 
patients with type 2 diabetes for cardiovascular risk reduction. 
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